Perianesthetic Implications and Considerations for Myasthenia Gravis.

Published

Journal Article

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease in which antibodies against the post-nicotinic acetylcholine receptor at the neuromuscular junction develop. Although the exact cause of MG remains unknown, the thymus is a common factor in many cases. Patients with underlying junctional disease, such as MG, have greater anesthesia-related risks because of their known predisposition toward prolonged muscle weakness. Medications given in the perioperative period, such as anesthetic agents, antibiotics, cardiovascular drugs, and corticosteroids, affect neuromuscular transmission that contributes to muscle weakness. Judicious use of neuromuscular blocking agents for patients with MG must be considered. This patient population is at high risk for respiratory failure, and therefore must be carefully assessed throughout the perioperative period to ensure that a regular spontaneous respiratory pattern is sufficient to provide adequate oxygenation. Perianesthesia providers must consider anesthetic, ventilatory, and pharmacologic implications when proposing, providing, and recovering anesthesia for the patient with MG.

Full Text

Duke Authors

Cited Authors

  • Muckler, VC; O'Brien, JM; Matson, SE; Rice, AN

Published Date

  • February 2019

Published In

Volume / Issue

  • 34 / 1

Start / End Page

  • 4 - 15

PubMed ID

  • 29980408

Pubmed Central ID

  • 29980408

Electronic International Standard Serial Number (EISSN)

  • 1532-8473

International Standard Serial Number (ISSN)

  • 1089-9472

Digital Object Identifier (DOI)

  • 10.1016/j.jopan.2018.03.009

Language

  • eng